文献速递神经肿瘤

高危低级别胶质瘤的替莫唑胺放化疗及辅助化疗结局分析

Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
PubMed 文献 · World Neurosurg · 2021-07-07

该单中心回顾性研究纳入64例 aggressive/high-risk 低级别胶质瘤患者,均接受术后放疗(中位剂量55.8 Gy)联合同步替莫唑胺及辅助替莫唑胺化疗。中位随访56.7个月,5年无进展生存率和总生存率分别为74.6%和84.3%,毒性可耐受。

要点

  • 高危低级别胶质瘤 upfront 同步放化疗联合辅助替莫唑胺方案可行。
  • 5年PFS 74.6%,5年OS 84.3%,中位随访56.7个月。
  • 仅9%患者因毒性或早期进展提前终止辅助化疗。

核心结论

  • 对 aggressive/high-risk 低级别胶质瘤, upfront 替莫唑胺同步放化疗联合辅助替莫唑胺可获得可接受的生存结局且毒性适中。

研究设计与样本

  • 单中心回顾性研究,纳入2009–2016年诊断为 aggressive/high-risk 低级别胶质瘤的64例患者,中位初诊年龄38岁。

主要发现

  • 中位随访56.7个月,5年无进展生存率为74.6%,5年总生存率为84.3%。
  • 组织学亚型5年总生存率:少突胶质细胞瘤87.5%、混合少突星形细胞瘤90.4%、星形细胞瘤71.9%(P=0.42)。
  • 分子分型5年总生存率:少突胶质细胞瘤85.8%、IDH突变型星形细胞瘤90%、IDH野生型星形细胞瘤66.7%(P=0.87)。
  • 6例(9%)因毒性或早期疾病进展提前终止辅助替莫唑胺。

临床怎么用

  • 对具有临床影像学和/或组织形态学高危特征的 low-grade glioma,可考虑 upfront 放疗联合同步及辅助替莫唑胺化疗。

局限性

  • 回顾性单中心设计,样本量64例,分子分型仅在37例(58%)患者中完成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG). METHODS: Medical records of patients defined as aggressive/high-risk LGG based on clinicoradiologic and/or histomorphologic features treated between 2009 and 2016 in an academic neuro-oncology unit with upfront postoperative radiotherapy at time of initial diagnosis with concurrent and adjuvant TMZ were reviewed, retrospectively. RESULTS: In total, 64 patients with median age of 38 years at initial diagnosis were included. Histomorphologically, patients were classified into oligodendroglioma, mixed oligoastrocytoma, and astrocytoma. Molecular markers such as isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion were used to classify 37 of 64 (58%) patients into molecularly defined entities comprising oligodendroglioma (IDH-mutant with 1p/19q codeletion), IDH-mutant astrocytoma (immunohistochemistry or gene sequencing), and IDH-wild-type astrocytoma (gene sequencing). All 64 patients completed planned conventionally fractionated focal conformal radiotherapy (median dose 55.8 Gy) with concurrent TMZ. Fifty-nine patients received further adjuvant TMZ for a median of 12 cycles. Adjuvant TMZ was stopped prematurely in 6 (9%) patients due to toxicity or early disease progression. At a median follow-up of 56.7 months, 5-year Kaplan-Meier estimates of progression-free survival and overall survival for the study cohort were 74.6% and 84.3%, respectively. Five-year overall survival was 87.5%, 90.4%, and 71.9% for oligodendroglioma, mixed oligoastrocytoma, and astrocytoma, respectively (P = 0.42) Similar estimates for molecularly defined oligodendroglioma, IDH-mutant astrocytoma, and IDH-wild-type astrocytoma were 85.8%, 90%, and 66.7%, respectively (P = 0.87). CONCLUSIONS: Upfront TMZ-based concurrent radio-chemotherapy and adjuvant TMZ chemotherapy provides acceptable survival outcomes in aggressive/high-risk LGG with modest toxicity.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Anand S, Chatterjee A, Gupta T, et al. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. World Neurosurg. 2021. PMID: 34245877. doi:10.1016/j.wneu.2021.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。